158 results about "Healthy subjects" patented technology

The present invention provides a method, system, device, medium and program product for evaluating lung function based on the time characteristics of pulmonary electrical impedance images, and relates to the field of intelligent medical care. The method comprises: obtaining a time-series EIT image of a subject to be tested; obtaining regional time distribution diagrams corresponding to different exhaled air volumes of the subject to be tested containing time characteristics based on the time-series EIT image; and obtaining regional time distribution values ​​corresponding to different exhaled air volumes based on the regional time distribution diagram; comparing the regional time distribution value of the subject to be tested at the first exhaled air volume with the standard value of a healthy person at the first exhaled air volume, and if the regional time distribution value of the subject to be tested is greater than the standard value, outputting the result of the respiratory muscle burst difference of the subject to be tested.

The invention discloses application of FGL1 protein in preparation of a kit for diagnosing allergic rhinitis. It is found that the FGL1 protein content in the serum of a healthy subject and the FGL1 protein content in the serum of an allergic rhinitis patient are obviously different, and the FGL1 protein content in the serum of the allergic rhinitis patient is obviously higher than that of the healthy subject. A further diagnosis efficacy test shows that the FGL1 protein can effectively diagnose and distinguish healthy subjects and allergic rhinitis patients, the diagnosis accuracy is high, the FGL1 protein can be used for developing a kit for diagnosing allergic rhinitis, and the objectivity is obviously improved compared with an existing diagnosis method.

Aging in an individual refers to the temporal change, mostly decline, in the body's ability to meet physiological demands. Biological age (BA) is a biomarker of chronological aging, and can be used to stratify populations to predict certain age related chronic diseases. BA can be predicted from biomedical features such as brain MRI, retina or facial images, but the inherent heterogeneity in the aging process limits the usefulness of BA predicted from individual body systems. The methods disclosed herein teach a multi-modal Transformer-based architecture with cross-attention which was able to combine facial, tongue and retina images to estimate BA. The model was trained using facial, tongue and retina images from 11, 223 healthy subjects, and demonstrated that using a fusion of the three image modalities achieved the most accurate BA predictions. The approach was validated on a test population of 2,840 individuals with six chronic diseases, and obtained significant difference between chronological age (CA) and BA (AgeDiff) than that of healthy subjects. AgeDiff has the potential to be utilized as a standalonfe biomarker, or conjunctively alongside other known factors for risk stratification and progression prediction of chronic diseases. The results therefore highlight the feasibility of using multi-modal images to estimate and interrogate the aging process.

The invention belongs to the technical field of artificial intelligence, and discloses a signal data processing method of an Alzheimer's disease and frontotemporal dementia diagnosis method, which comprises the following steps: selecting an electroencephalogram channel by adopting PSO (Particle Swarm Optimization) and converting computer signal time sequence data into a time-frequency diagram by using wavelet transform, so as to realize accurate diagnosis of Alzheimer's disease patients and healthy subjects. And patients with frontotemporal dementia and healthy subjects as well as patients with Alzheimer's disease and patients with frontotemporal dementia can be accurately and efficiently classified. The PSO is used for selecting a channel combination with good electroencephalogram energy and reducing information interference caused by redundant electroencephalogram channels, a time-frequency graph obtained through wavelet transformation can provide time information and frequency information of electroencephalogram signals at the same time, the model can learn features more effectively, and the classification performance of the model is improved. According to the method disclosed by the invention, the accuracy of classification of the Alzheimer's disease patients and healthy subjects, the frontotemporal dementia patients and healthy subjects, and the Alzheimer's disease patients and the frontotemporal dementia patients is remarkably improved.

The present invention discloses a method for preventing or treating atrial fibrillation (AF) in a subject by administering a therapeutically effective amount of a flavonol compound (Formula 1 or a tautomer thereof), a pharmaceutically acceptable salt, hydrate, or solvate thereof. The method involves obtaining a subject in need of AF prevention or treatment, suspected to require such prevention or treatment, or a normal healthy subject, and administering the compound to the subject Formula 1 comprises specific atoms and substituents, including - H, -OCH3, -OH, -I, -Br, -F, or Cl. By utilizing the flavonol compound of Formula 1, the risk of AF development or the prevalence of AF in the subject is reduced, providing an effective approach for managing AF in individuals.

The invention discloses application of FN1 as a biomarker in diagnosis or auxiliary diagnosis of nasopharyngeal carcinoma. By detecting the serum FN1 level, healthy subjects and advanced nasopharyngeal carcinoma patients can be distinguished, early nasopharyngeal carcinoma patients and advanced nasopharyngeal carcinoma patients can be distinguished, VCA-IgA negative early nasopharyngeal carcinoma patients and advanced nasopharyngeal carcinoma patients can be distinguished, and VCA-IgA positive early nasopharyngeal carcinoma patients and advanced nasopharyngeal carcinoma patients can be distinguished. According to the present invention, the EBV DNA-negative early nasopharyngeal carcinoma patient and the EBV DNA-negative late nasopharyngeal carcinoma patient can be distinguished, the EBV DNA-positive early nasopharyngeal carcinoma patient and the EBV DNA-positive late nasopharyngeal carcinoma patient can be distinguished, the diagnosis sensitivity is high, the marker detection is convenient, rapid and non-invasive, and the good clinical application and promotion value can be provided.

A method for identifying biomarkers indicative of neurodegeneration using a covariance neural network (VNN) includes providing a VNN trained on brain anatomical data primarily composed of healthy subjects, making the largest proportion of the population in the data. Brain anatomical data of a subject is provided as input, and, based on the input, the VNN generates a set of biomarkers and a brain health marker indicative of neurodegeneration of the subject.

The invention discloses a PID (Proportion Integration Differentiation) electrical stimulation balance rehabilitation method based on a damage synergistic effect. According to the method, firstly, myoelectricity and IMU joint movement data of a healthy subject on a disturbance platform are collected, non-negative matrix factorization (NMF) is conducted on the myoelectricity data, and the muscle synergistic effect of the healthy subject under a disturbance normal form is solved; myoelectricity and IMU signals of stroke patients in the same disturbance normal form are collected, nonnegative matrix factorization is carried out on the myoelectricity of the patients, and similarity analysis is carried out on the health synergistic effect and the patient synergistic effect to determine the injury synergistic effect. The injury synergistic effect is applied to adjustment of electrical stimulation pulse width parameters and used for conducting electrical stimulation on lower limb muscles, joint angle data are collected in real time, PID electrical stimulation control based on the injury synergistic effect is achieved, and therefore a patient can track a joint angle track of a healthy subject under a disturbance normal form. The patient is assisted to recover the injury synergistic effect under the disturbance normal form, the balance capacity is improved, and a new path is developed for rehabilitation treatment of the stroke patient.

The invention discloses an application of a marker combination in prediction or diagnosis of gout, the marker combination comprises an immune cell subset and clinical data, and the immune cell subset comprises virus-specific cytotoxic NK cells and inhibitory Vdelta2 cells. The marker combination comprises immune cell subgroups and clinical data, different immune cell subgroups are matched with different clinical data when a gout attack stage and a gout remission stage are distinguished, or when the gout remission stage and a healthy subject are distinguished, and high-sensitivity and high-specificity diagnosis results are achieved. Therefore, the marker combination disclosed by the invention has a wide prospect in the aspect of predicting different processes of gout, and can provide more basic research data for health management of gout high-risk people.

A method for constructing a model for assessing the phenotypic state of a receiver and a phenotypic state model, a method for constructing a model for assessing the elastic homeostasis of a receiver and an elastic homeostasis model, a method for assessing the health state of a receiver, a method for assessing the elastic homeostasis of a receiver, a method for assessing the risk of a receiver suffering from a metabolic disease, a method for assessing whether a therapy for treating a metabolic disease of a receiver is effective, a method and system for assessing whether a metabolic health intervention solution of a receiver is effective, and a kit. The method for constructing a model for assessing the phenotypic state of a receiver comprises: selecting a plurality of markers that are involved in or affect a total of four categories of metabolism, that is, glycometabolism, lipid metabolism, amino acid metabolism and metabolic stress; selecting one to several categories as coordinate axes for establishing a model; collecting samples of n healthy receivers and samples of m receivers who are in an impaired-health or sub-healthy condition; measuring the levels of markers related to the selected coordinate axes in each sample; training a machine learning model by using the levels of the markers; and performing screening to obtain a target marker, and calculating a weight coefficient of the target marker, so as to establish the model for assessing the phenotypic state of the receiver.

The invention provides a metabolic marker combination for ovarian cancer diagnosis and application thereof, and belongs to the technical field of in-vitro diagnosis. The invention provides a metabolic marker combination for ovarian cancer diagnosis. The metabolic marker combination comprises phosphatidylcholine 34: 4, threonic acid, phosphatidylcholine 32: 2, pyroglutamic acid, phosphatidylcholine 36: 6 and ceramide d38: 2. According to the metabolic marker combination, plasma samples of a healthy subject and an ovarian cancer patient are analyzed, a group of biomarkers with significant difference are screened from the plasma samples, and the metabolic marker combination is a non-invasive, non-invasive and high-accuracy metabolic marker combination for distinguishing the healthy subject and the ovarian cancer patient. The method can be used for constructing a diagnostic model for distinguishing healthy subjects from ovarian cancer patients. The metabolic marker combination disclosed by the invention can be used for improving the diagnosis and evaluation capability of ovarian cancer patients, so that early discovery, early diagnosis and early intervention can be realized clinically, and the survival rate of the ovarian cancer patients is improved.

Provided herein is an RNA analysis method for detecting and quantifying RNA (such as RNA from an immune cell or from a cancer cell) and / or for identifying and quantifying immune cell types from which the RNA originated. In some embodiments, expression levels of genes differentially expressed between healthy subjects and subjects having a disease or disorder are determined based on the RNA. In some embodiments, immune cell types from which the RNA originated are identified and quantified. Provided herein are also methods for determining the likelihood that a subject has the disease or disorder, such as a cancer.

A method of detecting the level of 5-hydroxymethylcytosines (5-hmc) in a DNA molecule of a cell having a 5-hmc prevalence lower than 0.002% of total DNA bases is provided. The method comprising:(a) attaching a 5-hmc labeling agent to the DNA molecule; and(b) subjecting the DNA molecule to an imaging method suitable for detecting the labeling agent, thereby detecting the level of 5-hmc in the DNA molecule. Also provided is a method of diagnosing cancer in a subject in need thereof, the method comprising:(a) providing a DNA sample of a cell of the subject;(b) detecting the level of 5-hmc in the DNA sample as described herein; wherein a significant decrease in the level of 5-hmc in the DNA sample, as compared to a control DNA sample from a healthy subject is indicative that the subject has cancer.

The invention relates to neurodegenerative disorders, and particularly to diagnostic and prognostic methods, apparatus and kits for neurodegenerative disorders, such as mild cognitive impairment (MCI), Alzheimer's disease, Parkinson's disease, Huntington's disease or Motor Neurone disease. The invention also extends to methods of detecting novel biomarkers, and methods for treating patients diagnosed or prognosed with a neurodegenerative disorder. A mathematical correlation between the concentrations of Tau protein and T14 peptide is found in samples from healthy subjects without a mood disorder, but not in samples from subjects having neurodegenerative disorders or a predisposition thereto.

Pulse wave velocity (PWV) is a measure of arterial stiffness and a cardiovascular disease risk factor. Accurate PWV estimation is difficult due to complex arterial dynamics, such as longitudinal motion and natural tissue oscillations. This present disclosure relates to a robust, motion-resistant PWV estimation framework including: 1) tracking and compensating for arterial longitudinal wall motions, 2) suppressing undulating arterial motion via common mode rejection, and 3) enhancing differential signals to extract wall expansion. In vitro experiments with induced lateral motion indicate the framework's PWV estimates (6.19±0.33 m / s) closely matched reference values (6.26±0.12 m / s; error: 1.1%), outperforming methods without motion compensation (4.46±1.78 m / s; error: 28.8%). In vivo trials with five healthy subjects showed an average PWV of 4.18±0.56 m / s using the motion-resistant method, compared to 2.54±0.95 m / s without motion compensation (p<0.005). This framework enhances PWV estimation reliability, offering clinical potential for better arterial stiffness assessment and cardiovascular risk stratification.

Disclosed are methods to generate biomarkers that can be used for detection of phenotypes in patients. In an example, a method includes obtaining, from a cohort of subjects, a first plurality of samples from healthy subjects and a second plurality of samples from subjects with a phenotype, and generating sequencing data for the samples. The sequencing data may be used to generate a file having a file format (e.g., a.cpg file), and preliminary segmentation may be performed. Biomarker candidates may be generated by applying a model, and the biomarker candidates scored and / or prioritized to obtain biomarkers for a phenotype. The biomarkers may subsequently be used in a panel to detect the phenotype in a subject.

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

The invention relates to a brain anomaly network positioning method and system based on functional connection network mapping in the technical field of neural image data processing. The brain abnormal network positioning method comprises the following steps: calculating a whole brain function network diagram connected with each abnormal site by using resting state function connection data of large-scale health subjects based on a plurality of dispersed abnormal sites reported in previous literatures; then superposing the function network diagrams to obtain a network probability graph; and finally, filtering the probability graph through a threshold value to obtain a final core anomaly network graph. According to the method, the inherent functional connection architecture of the brain is used as a reference system, abnormal sites which seem to be uncorrelated in different researches are successfully traced and unified to a common and stable functional network, and compared with a single brain region marker, the generated network-level biomarker integrates more source evidences, so that the network-level biomarker has the advantages that the network-level biomarker can be widely applied to the field of biomarkers of the brain region. Therefore, the problems of result heterogeneity and inconsistency in brain abnormality discovery are solved.

The present invention relates to esters of formula (I) or pharmaceutically acceptable salts thereof and their use as medicaments, in particular for the treatment of skin diseases or skin cancer. The present invention further relates to the use of esters of formula (I) or pharmaceutically acceptable salts thereof in cosmetic and nutritional compositions for preventing or reducing the signs of aging in healthy subjects.

The invention discloses a primary hypertension risk assessment method based on infrared thermal imaging. The method comprises the following steps: (1) respectively taking two-hand infrared thermograms of a healthy subject, a hypertension patient and a hypertension patient before and after cold stimulation by adopting a medical infrared thermal imager; (2) analyzing hand infrared thermograms before and after cold stimulation of a healthy subject, a hypertensive patient and a hypertensive patient so as to reflect vascular reactivity and blood perfusion states of hands of the healthy subject, the hypertensive patient and the hypertensive patient; and (3) taking hand infrared thermograms of the to-be-tested subject before and after cold stimulation by adopting a medical infrared thermal imager, and obtaining a judgment result according to the vascular reactivity and blood perfusion state of the hand. According to the invention, a medical infrared thermal imager is utilized to shoot infrared thermograms of hands of a subject before and after cold stimulation, so that vascular reactivity and blood perfusion states are visually reflected in a non-contact, real-time and visualized manner, and finally, the purpose of evaluating the risk of primary hypertension is achieved.

The invention provides a brain metabolism network epicenter detection method and device. The method comprises the following steps: establishing a healthy brain network based on MRI brain imaging data of a healthy subject, wherein the healthy brain network comprises a structural network and a functional network which have the same brain network nodes; calculating a brain metabolism damage degree value L of each brain network node based on FDG-PET brain image data of a disease patient and a healthy subject; calculating probabilities P1 and P2 that each brain network node may be a brain metabolism network epicenter based on a healthy brain structure network and a functional network; comprehensively ranking the brain network nodes according to the sizes of L, P1 and P2, wherein several brain network nodes ranked at the front are brain metabolism network epicenter. The method can accurately detect the epicenter of the brain metabolism network, and has good robustness.

The present disclosure relates to an anti-fatigue Lactobacillus composition. The anti-fatigue Lactobacillus composition, which includes at least one of Lactobacillus brevis GKEX, Lactobacillus plantarum GKK1 and Lactobacillus johnsonii GKJ2 as an active ingredient, administered to a healthy subject for a continuous period of time, can significantly improve fatigue-related biochemical indices and prolong aerobic exercise time to exhaustion, and thus can be used as an active ingredient for preparation of various compositions for anti-fatigue and / or improving athletic ability.

A method of selecting a treatment for a subject having cancer is disclosed. The method comprises:(a) determining a level of catalytic activity of at least one DNA repair enzyme in a biological sample of the subject; and(b) selecting an immune checkpoint regulator as a treatment for a subject having a statistically significant different level of catalytic activity of the DNA repair enzyme as compared to the catalytic activity of the DNA repair enzyme in a biological sample of a healthy subject.

The invention disclosed herein concerns screening and early detection of a variety of disease conditions in seemingly healthy subjects, enabling early intervention and treatment.

This invention relates to the field of rehabilitation training technology, and discloses a method for determining amblyopia perception training data and amblyopia perception training visual targets. The method includes: acquiring test data of the target subject, wherein the test data is data obtained from a basic amblyopia perception test of the target subject; determining the initial contrast sensitivity data of the target subject based on the test data; acquiring reference contrast sensitivity data, wherein the reference contrast sensitivity data is obtained from amblyopia perception tests of healthy subjects of the same age as the target subject; determining the target subject's weak data based on the initial contrast sensitivity data and the reference contrast sensitivity data; and determining the target subject's training data based on the weak data. This invention focuses on targeted training in weak areas, reducing ineffective training in normal areas, saving a significant amount of unnecessary training time, and improving the efficiency and targeting of amblyopia perception training.

The present invention provides the use of UTP6 in the preparation of a product for diagnosing polycystic ovary syndrome, relating to the field of biotechnology. Compared with healthy subjects, UTP6 is differentially expressed in patients with polycystic ovary syndrome. The expression of UTP6 is related to polycystic ovary syndrome, and the diagnosis of polycystic ovary syndrome can be achieved by detecting the expression level of UTP6. In addition, compared with healthy subjects, PIAS4 is differentially expressed in patients with polycystic ovary syndrome. The expression of PIAS4 is related to polycystic ovary syndrome, and the combined use of UTP6 and PIAS4 for the diagnosis of polycystic ovary syndrome has higher detection accuracy.

Non-invasive methods of detecting pathology of the bone marrow comprising receiving a metacell model of a plurality of metacell types based on single cell RNA sequencing (scRNA-seq) of CD34 positive cells from peripheral blood and comparing it to control values of metacells of CD34 positive cells from peripheral blood of healthy subjects are provided. Non-invasive methods of predicting the percentage of blasts in the bone marrow and of calculating an IPSS-M risk score are also provided, as are systems for performing the methods of the invention.

The present application relates to the field of biological science, and particularly relates to the use of a SCN11A protein detection reagent in the preparation of a depression screening and depression treatment effect evaluation kit. It is found for the first time that the expression level of SCN11A protein in the peripheral blood serum of a depression patient is significantly higher than that of a healthy subject. The reagent for detecting SCN11A protein is used in the preparation of a depression screening kit, so that effective screening of depression and evaluation of the treatment effect of depression can be realized.

The present invention discloses that cancer cells secrete succinate into extracellular milieu, which increases macrophage migration and mediates TAM polarization. Furthermore, succinate induces cancer cell EMT, enhances cancer cell migration, and promotes cancer metastasis in murine models. It is indicated in the present invention that serum succinate concentration is elevated in patients with lung cancer when compared to healthy subjects. It implies that during cancer development and progression, cancer cells release a large quantity of succinate into the circulation. As shown in the present invention, serum succinate has a high discriminatory power, it represents a new class of circulating oncometabolite with potential value for predicting NSCLC. Furthermore, as elevation of succinate level in LLC tumor model is accompanied by increased TAMs in the subcutaneous tumors and enhanced cancer metastasis, serum succinate may be a useful therapeutic biomarker for NSCLC treatment. The present invention also provides an anti-succinate antibody that can serve as a cancer therapeutic agent.

A method and system enabling a determination of the risk of developing breast cancer of a subject, comprises using a magnetic resonance spectroscopy device to obtain the level of the spectral signal at 3.15 and 3.19 ppm, within the breast tissue of the subject, and comparing the level of the spectral signal obtained in the first step with a reference level of a spectral signal at 3.15 and 3.19 ppm of the breast of a healthy subject, to determine whether the level of the signal obtained in the first step exceeds the reference level of a healthy subject is comparable to that of a subject known to be at elevated risk; or is elevated to the level of persons known to be carrying a gene mutation.